51 results on '"Lacouture, Mario E'
Search Results
2. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern
3. A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash
4. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
5. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
6. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
7. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
8. Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center
9. Reply to: “Skin moisturization for xerosis related to targeted anticancer therapies”
10. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
11. Incidence and risk of xerosis with targeted anticancer therapies
12. Clinico-morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients
13. Differential Radiation Dermatitis in Native Skin and an Autologous Transplanted Myocutaneous Flap
14. Current Practices in the Management of Adverse Events Associated With Targeted Therapies for Advanced Renal Cell Carcinoma: A National Survey of Oncologists
15. Ipilimumab in patients with cancer and the management of dermatologic adverse events
16. Dermoscopic Findings in Cutaneous Metastases
17. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
18. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
19. Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
20. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
21. Tracking of Second Primary Melanomas in Vemurafenib-Treated Patients
22. Incidence of alopecia from endocrine therapies in cancer: P6446
23. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
24. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization
25. Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
26. Clinical and Histopathologic Characteristics of Rash in Cancer Patients Treated With Mammalian Target of Rapamycin Inhibitors
27. The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis
28. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
29. Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis
30. The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status
31. Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents
32. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
33. Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma
34. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies
35. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
36. Cutaneous and mucosal reactions to oncologic therapy
37. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
38. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life
39. Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma
40. Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
41. Dermatologic issues in adult survivors of childhood cancer
42. Blackberry-induced hand-foot skin reaction to sunitinib
43. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy
44. Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
45. Completeness in the Reporting of Dermatologic Adverse Drug Reactions Associated with Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors in Phase II and III Colorectal Cancer Clinical Trials
46. An Interdisciplinary Consensus on Managing Skin Reactions Associated With Human Epidermal Growth Factor Receptor Inhibitors
47. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
48. Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
49. KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castlemanʼs disease and Kaposiʼs sarcoma
50. The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.